Drugs for Lymphocele (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 18)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Heparin, bovine |
Approved, Investigational, Withdrawn |
Phase 4 |
|
9005-49-6 |
22833565 9812414 772 |
Synonyms:
Adomiparin
alpha-Heparin
Ariven
Arteven
Bemiparin
BOVINE HEPARIN
Calcilean
CALCIPARINE
Certoparin
CLEXANE
Clexane®|enoxaparin sodium|Lovenox®|PK-10169|RP-54563
Clivarin
Clivarine
DALTEPARIININATRIUM
Dalteparin
DALTEPARIN SODIUM
dalteparin sodium|Fragmin®
DALTEPARIN SODNÁ SŮL
DALTEPARIN SODYUM
DALTEPARINA SODICA
DALTEPARINA SÓDICA
DALTEPARINE SODIQUE
DALTÉPARINE SODIQUE
DALTEPARINNATRIUM
DALTEPARIN-NATRIUM
DALTEPARIN-NÁTRIUM
DALTEPARINO NATRIO DRUSKA
DALTEPARINUM NATRICUM
DALTEPARYNA SODOWA
Depo-Heparin
ENOXAPARIN
ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE)
ENOXAPARIN SODIUM SALT
Eparina
Eparina [DCIT]
Fluxum
FR-860
FRAGMIN
Fragmin A
Fragmin B
Fraxiparin
Hed-Heparin
Hepalean
HEPARIN
Heparin Cy 216
|
HEPARIN FRAGMENT KABI 2165
Heparin Leo
Heparin Lock Flush
HEPARIN SODIUM
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparina
HEPARINATE
Heparine
HEPARINIC ACID
Heparinsodiumsalt
Heparinum
Hepathrom
HepFlush®
HEP-LOCK
KABI-2165
Leparan
Lipo-Hepin
LIQUAEMIN
Liquaemin Sodium
Liquemin
LOVENOX
LOVENOX (PRESERVATIVE FREE)
LOW LIQUEMINE
Low molecular weight heparin sodium
Multiparin
Novoheparin
Pabyrin
PANHEPRIN
Parnaparin
Parnaparin sodium
Parvoparin
PK-10169
Pularin
Reviparin
RP-54563
Sandoparin
SODIUM HEPARIN
Sublingula
TEDELPARIN
Thromboliquine
Unfractionated heparin
Vetren
Vitrum AB
|
|
2 |
|
Hemostatics |
|
Phase 4 |
|
|
|
3 |
|
Coagulants |
|
Phase 4 |
|
|
|
4 |
|
Fibrinolytic Agents |
|
Phase 4 |
|
|
|
5 |
|
Anticoagulants |
|
Phase 4 |
|
|
|
6 |
|
Calcium heparin |
|
Phase 4 |
|
|
|
7 |
|
Lanreotide |
Approved |
Phase 3 |
|
108736-35-2 |
71349 6918011 |
Synonyms:
188Re-Lanreotide
2-{[(19-{[2-amino-1-hydroxy-3-(naphthalen-2-yl)propylidene]amino}-10-(4-aminobutyl)-6,9,12,15,18-pentahydroxy-16-[(4-hydroxyphenyl)methyl]-13-[(1H-indol-3-yl)methyl]-7-(propan-2-yl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-4-yl)(hydroxy)methylidene]amino}-3-hydroxybutanimidate
2-Naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide
BIM 23014
BIM 23014|DC 13-116|lanreotide acetate|Somatuline®
DC 13-116
Lanreotida
Lanreotide
Lanreotide acetate
Lanreotide acetic acid
Lanreotide-SR
|
L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide
Nal-cyclo(cys-tyr-TRP-lys-val-cys)THR-NH2
Nal-cyclo(cys-tyr-TRP-lys-val-cys)-THR-NH2
Naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide
Naphthyl-cyclo(cys-tyr-TRP-lys-val-cys)THR-NH2
Somatulin
Somatulina
Somatuline
SOMATULINE AUTOGEL
SOMATULINE LA
|
|
8 |
|
Somatostatin |
Approved, Investigational |
Phase 3 |
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
9 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
10 |
|
Fibrin Tissue Adhesive |
|
Phase 3 |
|
|
|
11 |
|
Hormones |
|
Phase 3 |
|
|
|
12 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
13 |
|
Pasireotide |
Approved |
Phase 2 |
|
396091-73-9 |
56841596 9941444 |
Synonyms:
cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)
Pasireotida
Pasireotide
Pasiréotide
pasireotide diaspartate|Signifor®|SOM 230|SOM 320|SOM-230
|
Pasireotidum
SIGNIFOR
SOM 230
SOM230
SOM-230
|
|
14 |
|
Thrombin |
Approved, Investigational |
|
|
|
|
Synonyms:
coagulation factor II
THROMBIN
Thrombin bovine
|
Thrombin, Topical (Bovine)
THROMBOSTAT
|
|
15 |
|
Octreotide |
Approved, Investigational |
|
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-19-{[(2R)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
19-[(2-Amino-1-hydroxy-3-phenylpropylidene)amino]-10-(4-aminobutyl)-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
Compound 201 995
Compound 201995
Compound 201-995
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulphide
DRG-0115|Mycapssa®|Sandostatin®|SMS 201,995
Octreotida
Octreotide
Octreotide acetate
OCTREOTIDE ACETATE (PRESERVATIVE FREE)
OCTREOTIDE ACETATE PRESERVATIVE FREE
Octreotide acetate salt
Octreotidum
|
Octrotide
Sandostatin
SANDOSTATIN LAR
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SMS 201-995
SMS 201-995 AC
SMS-201-995
SMS-201-995 AC
SMS-201995-AC
SMS995
SMS-995
|
|
16 |
|
Pharmaceutical Solutions |
|
|
|
|
|
17 |
|
Antineoplastic Agents, Hormonal |
|
|
|
|
|
18 |
|
Gastrointestinal Agents |
|
|
|
|
|
Interventional clinical trials:
(show all 25)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Does Intraoperative Application of TachoSil Reduce the Number of Lymphocele After Pelvic Lymphadenectomy? |
Completed |
NCT03752606 |
Phase 4 |
|
2 |
Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer. |
Completed |
NCT02001857 |
Phase 4 |
1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery. |
3 |
A Randomized Controlled Trial for PREvention of VENous ThromboEmbolism Following Radical Prostatectomy (PREVENTER Trial) |
Terminated |
NCT03006562 |
Phase 4 |
Subcutaneous Heparin |
4 |
Prevention of Pelvic Lymphocele by Floseal During Pelvic Lymphadenectomy for Gynecologic Cancer: a Pilot Study |
Unknown status |
NCT01974193 |
Phase 3 |
Floseal |
5 |
Efficacy of a Fibrin Sealant (Tissucol Duo®) for the Prevention of Lymphocele After Laparoscopic Pelvic Lymphadenectomy Due to Gynaecological Cancer: a Randomised Controlled Trial |
Completed |
NCT03914963 |
Phase 3 |
|
6 |
Evaluation of the Efficacity of Lanreotide LP 90 mg to Minimized the Lymphorrhea Post Axillary Lymphadenectomy in Breast Cancer |
Completed |
NCT00630695 |
Phase 3 |
Lanreotide LP 90;Placebo lanreotide |
7 |
Application of the Biological Fibrin Based Adhesive for the Prevention of Surgical Complications in the Kidney Transplant |
Completed |
NCT01631448 |
Phase 3 |
|
8 |
Observation Versus Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer: A Phase 3 Prospective Multi-institutional Randomised Controlled Trial |
Recruiting |
NCT03071289 |
Phase 3 |
Cisplatin |
9 |
Evaluation of the Effect of Pasireotide LAR Administration in the Lymphocele Prevention After Axillary Node Dissection for Breast Cancer |
Completed |
NCT01356862 |
Phase 2 |
PASIREOTIDE;PLACEBO |
10 |
Management of Symptomatic Post-operative Lymphocele With an Patient-controlled, Vascular Catheter: A Validation Study |
Unknown status |
NCT02800980 |
|
|
11 |
PREvention of Post-mastectomy LYMphoceles by PAdding. A Randomized Prospective Multicenter Study |
Unknown status |
NCT02894021 |
|
|
12 |
Application of Thrombin Gel Matrix for the Prevention of Lymphocele in Patients With Endometrial Cancer. |
Completed |
NCT04205864 |
|
Thrombi-Gel |
13 |
A Randomized Control Trial for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection |
Completed |
NCT02476357 |
|
|
14 |
THE ROLE OF FLOSEAL IN THE PREVENTION OF LYMPHOCELE AND LYMPHATIC ASCITES AFTER LYMPH NODE DISSECTION FOR GYNECOLOGIC CANCER: A RANDOMIZED CONTROLLED TRIAL |
Completed |
NCT01679483 |
|
FloSeal application |
15 |
The Effect of a Peritoneal Iliac Flap on Lymphocele Formation After Robotic Radical Prostatectomy |
Completed |
NCT03567525 |
|
|
16 |
Management of a Giant Lymphocele Following Varicose Vein Surgery - A Case Report |
Completed |
NCT05398458 |
|
|
17 |
Impact of Peritoneal Closure and Retroperitoneal Drainage on Patients Who Underwent Laparotomic Retroperitoneal Lymph Node Dissection for Early Gynecological Cancer |
Completed |
NCT03765320 |
|
|
18 |
A Randomized Study Evaluating the Efficacy of the Synthetic Adhesive Solution Ifabond, in Reducing Seroma Formation Post Surgery in Breast Cancer Patients, When Used in Partial Mastectomy With or Without Axillary Lymph Node Dissection |
Completed |
NCT01742975 |
|
|
19 |
Prospective Open Randomized Study to Evaluate the Efficiency of Prophylactic Fenestration of the Peritoneum in Kidney Transplantation in Preventing the Occurrence of Postoperative Lymphoceles |
Completed |
NCT01206868 |
|
|
20 |
A Pilot Clinical Trial for the Prevention of Lymphoceles After Robotic Pelvic Lymph Node Dissections for Prostate Malignancies Using the da Vinci® EndoWrist® One™ Vessel Sealer |
Completed |
NCT02035475 |
|
|
21 |
Application of Cold Plasma Energy for Reduction of Lymphoceles Following Pelvic Lymph Node Dissection During Robot-Assisted Radical Prostatectomy |
Completed |
NCT02658851 |
|
|
22 |
Prospective Randomized Trial Evaluating the Effect of Peritoneal Flap Fixation on Symptomatic and Radiologic Lymphocele Formation Following Robot Assisted Radical Prostatectomy With Extended Pelvic Lymph Node Dissection (PerFix) |
Recruiting |
NCT04853095 |
|
|
23 |
Use of Compression Bandages in the Prevention of Post-mastectomy Lymphoceles |
Recruiting |
NCT04819542 |
|
|
24 |
Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation In Patients With Breast Cancer |
Terminated |
NCT03791736 |
|
|
25 |
A Pilot Clinical Trial for the Prevention of Postoperative Lymphoceles Using Absorbable Micorporous Polysaccharide Hemosphere Particles During Robotic Assisted Prostatectomy With Lymph Node Dissection |
Terminated |
NCT01644136 |
|
|
Cochrane evidence based reviews: lymphocele
|